Limited Mobile Version
Follow this company and never miss a research update
XVIVO

Xvivo Perfusion

Research note

Print

Xvivo Perfusion: First clinical heart transplant performed

Xvivo Perfusion has announced that the first clinical heart transplant has been performed using the company's technology for warm perfusion. Today’s news was expected and will not result in any changes in our valuation of the company.

Xvivo Perfusion is currently developing a machine (HS1) and a solution (Heartadex) that can be used for warm heart perfusion. The core technology is similar to that of XPS and STEEN Solution, where the organ is machine-perfused before being transplanted. The state of the organ can thereby be objectively evaluated, resulting in a more accurate assessment of the organ's quality. The process also has a cleansing effect on the organ. Pre-clinical results indicate that both longer preservation time and better organ quality can be achieved. 

Download our latest Research Report from 2017-07-28

Download full report icon-download